Search

Your search keyword '"Mohamed, A. S. A."' showing total 3 results
Start Over Author "Mohamed, A. S. A." Topic covid-19 Topic tocilizumab
3 results on '"Mohamed, A. S. A."'

1. Cryptococcemia in a patient with COVID‐19: A case report

Author

Khatib, Mohamad Y., Ahmed, Amna A., Shaat, Said B., Mohamed, Ahmed S., and Nashwan, Abdulqadir J.

Subjects
tocilizumab, lcsh:R5-920, COVID‐19, cryptococcemia, lcsh:R, Cryptococcus neoformans, lcsh:Medicine, Case Report, Case Reports, General Medicine, lcsh:Medicine (General), corticosteroids
Abstract

The authors urge clinicians to balance the use of Immunosuppressant drugs and tocilizumab for COVID‐19 patients to avoid the development of infections like Cryptococcemia, leading to death within 30 days.

Published
2021

2. Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

Author

Khatib, Mohamad Y., Shaik, Karimulla S., Ahmed, Amna A., Alwraidat, Mohammad A., Mohamed, Ahmed S., Abou Kamar, Mohamad R., Sharaf Eldean, Mouhammad Z., Aldaraiseh, Bashar K., and Nashwan, Abdulqadir J.

Subjects
tocilizumab, Medicine (General), R5-920, COVID‐19, double‐barrel colostomy, lower gastrointestinal bleeding, Medicine, Case Report, cytomegalovirus colitis, Case Reports, General Medicine
Abstract

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life‐threatening bleeding and mortality.

Published
2020
Full Text
View/download PDF

3. Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19.

Author

Khatib, Mohamad Y., Shaik, Karimulla S., Ahmed, Amna A., Alwraidat, Mohammad A., Mohamed, Ahmed S., Abou Kamar, Mohamad R., Sharaf Eldean, Mouhammad Z., Aldaraiseh, Bashar K., and Nashwan, Abdulqadir J.

Subjects
COVID-19, COLITIS, CYTOMEGALOVIRUSES, GASTROINTESTINAL hemorrhage, CYTOMEGALOVIRUS diseases
Abstract

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life‐threatening bleeding and mortality. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results